New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.

New therapeutics for the treatment of glycosphingolipid lysosomal storage diseases.

Glycosphingolipid lysosomal storage diseases are a small but challenging group of human disorders to treat. Although these appear to be monogenic disorders where the catalytic activity of enzymes in glycosphingolipid catabolism is impaired, the presentation and severity of disease is heterogeneous....

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Butters, T, Dwek, R, Platt, F
Formaat:	Journal article
Taal:	English
Gepubliceerd in:	2003

Gelijkaardige items

Glycosphingolipid lysosomal storage diseases: therapy and pathogenesis.
door: Jeyakumar, M, et al.
Gepubliceerd in: (2002)

Inhibition of glycosphingolipid biosynthesis: application to lysosomal storage disorders.
door: Butters, T, et al.
Gepubliceerd in: (2000)

Substrate deprivation: a new therapeutic approach for the glycosphingolipid lysosomal storage diseases.
door: Platt, F, et al.
Gepubliceerd in: (2000)

New developments in treating glycosphingolipid storage diseases.
door: Platt, F, et al.
Gepubliceerd in: (2005)

Glycosphingolipid profiling of tissues from mouse models of human lysosomal storage disorders
door: Priestman, D, et al.
Gepubliceerd in: (2008)

Lysosomal storage of oligosaccharide and glycosphingolipid in imino sugar treated cells.
door: Boomkamp, S, et al.
Gepubliceerd in: (2010)

Therapeutic applications of imino sugars in lysosomal storage disorders.
door: Butters, T, et al.
Gepubliceerd in: (2003)

Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases
door: Silk, J, et al.
Gepubliceerd in: (2005)

Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases.
door: Gadola, S, et al.
Gepubliceerd in: (2006)

Small-molecule therapeutics for the treatment of glycolipid lysosomal storage disorders.
door: Butters, T, et al.
Gepubliceerd in: (2003)

Storage solutions: treating lysosomal disorders of the brain.
door: Jeyakumar, M, et al.
Gepubliceerd in: (2005)

N-butyldeoxygalactonojirimycin: a more selective inhibitor of glycosphingolipid biosynthesis than N-butyldeoxynojirimycin, in vitro and in vivo.
door: Andersson, U, et al.
Gepubliceerd in: (2000)

Iminosugar inhibitors for treating the lysosomal glycosphingolipidoses
door: Butters, T, et al.
Gepubliceerd in: (2005)

Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses.
door: Butters, T, et al.
Gepubliceerd in: (2005)

Cellular effects of deoxynojirimycin analogues: uptake, retention and inhibition of glycosphingolipid biosynthesis.
door: Mellor, H, et al.
Gepubliceerd in: (2004)

Modulation of THP-1 macrophage and cholesterol-loaded foam cell apolipoprotein E levels by glycosphingolipids.
door: Garner, B, et al.
Gepubliceerd in: (2002)

The development and use of small molecule inhibitors of glycosphingolipid metabolism for lysosomal storage diseases
door: James A. Shayman, et al.
Gepubliceerd in: (2014-07-01)

Substrate reduction therapy for glycosphingolipid storage disorders.
door: Lachmann, R, et al.
Gepubliceerd in: (2001)

Pharmacological impairment of acrosome formation and sperm head morphogenesis reveals essential role of glycosphingolipids in spermiogenesis
door: van der Spoel, A, et al.
Gepubliceerd in: (2002)

Glycosphingolipid dysregulation and lysosomal dysfunction in motor neuron disease
door: da Silva Santos, CS
Gepubliceerd in: (2021)

ALTERED AUTOPHAGY AND APP METABOLISM IN GLYCOSPHINGOLIPID STORAGE DISEASES
door: Boland, B, et al.
Gepubliceerd in: (2011)

Molecular requirements of imino sugars for the selective control of N-linked glycosylation and glycosphingolipid biosynthesis
door: Butters, T, et al.
Gepubliceerd in: (2000)

Changes in glycosphingolipid levels in plasma and cerebrospinal fluid of individuals with Lysosomal Free Sialic Acid Storage Disorder
door: Marya S. Sabir, et al.
Gepubliceerd in: (2025-01-01)

Glycosphingolipid disorders of the brain.
door: Boomkamp, S, et al.
Gepubliceerd in: (2008)

Lysosomal dysfunction and glycosphingolipid dysregulation in rare and common neurodegenerative diseases
door: Huebecker, M
Gepubliceerd in: (2019)

Introduction: Glycosphingolipids in cell biology and disease.
door: Sillence, D, et al.
Gepubliceerd in: (2004)

Analysis of fluorescently labeled glycosphingolipid-derived oligosaccharides following ceramide glycanase digestion and anthranilic acid labeling.
door: Neville, D, et al.
Gepubliceerd in: (2004)

Lysosomal storage diseases
door: Platt, F, et al.
Gepubliceerd in: (2018)

Glycosphingolipids and Infection. Potential New Therapeutic Avenues
door: Johannes M. F. G. Aerts, et al.
Gepubliceerd in: (2019-12-01)

Lysosomal Ca(2+) homeostasis: role in pathogenesis of lysosomal storage diseases.
door: Lloyd-Evans, E, et al.
Gepubliceerd in: (2011)

Accumulation of glycosphingolipids in Niemann-Pick C disease disrupts endosomal transport.
door: te Vruchte, D, et al.
Gepubliceerd in: (2004)

Glycosphingolipid storage leads to the enhanced degradation of the B cell receptor in Sandhoff disease mice.
door: te Vruchte, D, et al.
Gepubliceerd in: (2010)

Inhibition of substrate synthesis as a strategy for glycolipid lysosomal storage disease therapy.
door: Platt, F, et al.
Gepubliceerd in: (2001)

Increased glycosphingolipid levels in serum and aortae of apolipoprotein E gene knockout mice.
door: Garner, B, et al.
Gepubliceerd in: (2002)

Emptying the stores: lysosomal diseases and therapeutic strategies
door: Platt, F
Gepubliceerd in: (2017)

Glycosphingolipids in endocytic membrane transport.
door: Sillence, D, et al.
Gepubliceerd in: (2004)

Diverse endogenous antigens for mouse NKT cells: self-antigens that are not glycosphingolipids.
door: Pei, B, et al.
Gepubliceerd in: (2011)

Pharmacotherapeutic strategies using small molecules for the treatment of glycolipid lysosomal storage disorders.
door: Butters, T
Gepubliceerd in: (2007)

Therapeutic Approaches in Lysosomal Storage Diseases
door: Carlos Fernández-Pereira, et al.
Gepubliceerd in: (2021-11-01)

The apo E gene knockout mouse as a model to study the potential atherogenic properties of glycosphingolipids
door: Garner, B, et al.
Gepubliceerd in: (2003)